Blood use strategies in urologic surgery

Urology

Volumn 55, Issue 4, 2000, Pages 461-467

  Gilbert, W Barritt ^a   Smith Jr , Joseph A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BLOOD; BLOOD DONOR; BLOOD TRANSFUSION; ERYTHROCYTE; HUMAN; OXYGENATION; PRIORITY JOURNAL; RISK FACTOR; UROLOGIC SURGERY;

EID: 0034020330     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00534-8     Document Type: Review

References (37)

1. Consensus conference: perioperative red blood cell transfusion. JAMA 260: 2700-2703, 1988.
2. Practice strategies for elective red blood cell transfusion. Ann Intern Med. 116:1992;403-406.
3. Carson J.L., Terrin M.L., Barton F.B., et al. A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion. 38:1998;522-529.
4. Mangano D.T., Browner W.S., Hollenberg M., et al. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. N Engl J Med. 323:1990;1781-1788.
5. Rao T.L.K., Montoya A. Cardiovascular, electrocardiographic and respiratory changes following acute anemia with volume replacement in patients with coronary artery disease. Anesth Dev. 12:1985;49-54.
6. Heyland D.K., Cook D.J., King D., et al. Maximizing oxygen delivery in critically ill patients a methodologic appraisal of the evidence . Crit Care Med. 24:1996;517-524.
7. Goodnough L.T., Brecher M.D., Kanter M.H., et al. Transfusion medicine (second of two parts) blood conservation . N Engl J Med. 340:1999;525-533.
8. Goodnough L.T., Brecher M.D., Kanter M.H., et al. Transfusion medicine (first of two parts) blood transfusion . N Engl J Med. 340:1999;438-447.
9. Ford C.D., Van Moorleghem G., Menlove R.L. Blood transfusions and postoperative wound infections. Surgery. 113:1993;603-607.
10. Heiss M.M., Mempel W., Delanoff C., et al. Blood transfusion-modulated tumor recurrence first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery . J Clin Oncol. 12:1994;1859-1867.
11. Jensen L.S., Kissmeyer-Nielsen P., Wolff B., et al. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet. 348:1996;841-845.
12. Burrows L, and Tartter P. Effect of blood transfusion on colonic malignancy recurrence rate. Lancet 2: 662, 1982.
13. Mikulin T., Powell C.S., Urwin G.H., et al. Relation between blood transfusion and survival in renal adenocarcinoma. Br J Surg. 73:1986;1036-1037.
14. Davies A.H., Cranston D., Ramarakha P., et al. Effect of blood transfusion on survival after radiotherapy as treatment for carcinoma of the prostate. Ann R Coll Surg. 73:1991;116-118.
15. McClinton S., Moffat L.E.F., Scott S., et al. Blood transfusion and survival following surgery for prostatic cancer. Br J Surg. 77:1990;140-142.
16. Sazama K. Reports of 35 transfusion-associated deaths 1976 through 1985 . Transfusion. 30:1990;583-590.
17. Linden J.V., Tourault M.A., Scribner C.L. Decrease in frequency of transfusion fatalities. Transfusion. 37:1997;243-244.
18. Ness P.M., Shirley R.S., Thomas S.K., et al. The differentiation of delayed serologic and delayed hemolytic transfusion reactions incidence, long-term serologic findings, and clinical significance . Transfusion. 30:1990;688-693.
19. Cookson ST, Arduino MJ, Aguero SM, et al., for the Yersinia Study Group: Yersinia enterocolitica-contaminated red blood cells - an emerging threat to blood safety, in Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996. Washington, DC, American Society for Microbiology, 1996, p 237.
20. Popovsky M.A., Moore S.B. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 25:1985;573-577.
21. Gilbert J.B., Malkowicz S.B., Wein A.J. Cell saver and radical retropubic prostatectomy analysis of cost-effectiveness . Urology. 46:1995;542-544.
22. Renner S.W., Howanitz P.J., Bachner P. Preoperative autologous blood donation in 612 hospitals a College of American Pathologists' Q-Probes study of quality issues in transfusion practice . Arch Pathol Lab Med. 116:1992;613-619.
23. Koch M.O., Smith J.A. Blood loss during radical prostatectomy is preoperative autologous blood donation indicated? J Urol. 156:1996;1077-1079.
24. Oefelein M.G., Colangelo L.A., Rademaker A.W., et al. Intraoperative blood loss and prognosis in prostate cancer patients undergoing radical retropubic prostatectomy. J Urol. 154:1995;442-447.
25. Shir Y., Raja S.N., Frank S.M., et al. Intraoperative blood loss during radical retropubic prostatectomy epidural versus general anesthesia . Urology. 45:1995;993-999.
26. Goodnough L.T., Grishaber J.E., Birkmeyer J.D., et al. Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures. Urology. 44:1994;226-231.
27. Giordano G.F., Giordano D.M., Wallace B.A., et al. An analysis of 9,918 consecutive perioperative autotransfusions. Surg Gynecol Obstet. 176:1993;103-110.
28. Clagett G.P., Valentine R.J., Jackson M.R., et al. A randomized trial of intraoperative autotransfusion during aortic surgery. J Vasc Surg. 29:1999;22-30.
29. Monk T.G., Goodnough L.T., Birkmeyer J.D., et al. Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy. Transfusion. 35:1995;559-565.
30. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet. 341:1993;1227-1232.
31. De Andrade J., Jove M., Landon G., et al. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop. 25:1996;533-542.
32. Faris P., Ritter M., Abels R., et al. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having major orthopaedic operation. J Bone Joint Surg. 78A:1996;62-72.
33. Adamson J.W., Spivak J.L. Physiologic basis for the pharmacologic use of recombinant human erythropoietin in surgery and cancer treatment. Surgery. 115:1994;7-15.
34. Goldberg M.A., McCutchen J.W., Jove M., et al. A safety and efficacy comparison of two dosing requirements of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop. 25:1996;544-552.
35. D'Ambria M. Preoperative epoitin alpha reduces transfusion requirements in coronary artery bypass graft surgery. Semin Hematol. 33:(suppl 2):1997;73-74.
36. Dubois R.W., Lim D., Hebert P., et al. The development of indications for the preoperative use of recombinant erythropoietin. Can J Surg. 41:1998;351-365.
37. Chen T.Y., Martin S., Lepor M. Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy. Urology. 50:1997;727-732.